Michaël Degaud

Dr. Michaël Degaud

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in British Journal of Haematology
Verified
Journal Article
Open access
CBClotilde Bravetti
Clotilde Bravetti
MDMichaël Degaud
Michaël Degaud
MAMarine Armand
Marine Armand
ESElise Sourdeau
Elise Sourdeau
KMKarima Mokhtari
Karima Mokhtari
FDFrédéric Davi
Frédéric Davi
Summary: Diagnosis of primary central nervous system lymphoma (PCNSL) is challenging, and although brain biopsy remains the gold standard, cerebrospinal fluid (CSF) constitutes a less invasive source of lymphomatous biomarkers. In a retrospective cohort of 54 PCNSL cases tested at diagnosis or relapse, we evaluated the contribution of immunoglobulin heavy chain (IGH) gene clonality and MYD88 L265P detection on both CSF cell pellets and supernatants, in comparison with cytology, flow cytometry, interleukin (IL)‐10 and IL‐6 quantification. Clonality assessment included a new assay to detect partial IGH‐DJ rearrangements. Clonal IGH rearrangements and/or MYD88 L265P mutation were detected in 27 (50%) cell pellets and 24 (44%) supernatant cell‐free (cf) DNA. Combining analyses on both compartments, 36 (66%) cases had at least one detectable molecular marker, present only in cfDNA for 9 (16%) of them. While cytology and flow cytometry were positive in only 7 (13.0%) and 9 (17.3%) cases respectively, high IL‐10 levels were observed in 36 (66.7%) cases. Overall, taking into account molecular and cytokine results, 46/54 (85%) cases had at least one lymphomatous biomarker detectable in the CSF. These results show that this combination of biomarkers evaluated on both cell pellet and supernatant CSF fractions improves significantly the biological diagnosis of PCNSL.

4 September 2025 in Blood
Verified
Journal Article
Closed access
DGDylan C. Gagler
Dylan C. Gagler
HGHussein Ghamlouch
Hussein Ghamlouch
DZDi Zhang
Di Zhang
PBPatrick Blaney
Patrick Blaney
ATAvital Tenenbaum
Avital Tenenbaum
GMGareth J. Morgan
Gareth J. Morgan
We carried out a single-cell multiomic analysis on a series of MYD88-mutated Waldenström macroglobulinemia (WM) patients and identified 2 distinct subtypes of disease, memory B-cell (MBC)–like and plasma cell (PC)–like, based on their expression of key lineage defining genes. Biologically, the subtypes are characterized by their variable capacity to differentiate fully toward a PC and exhibit unique transcriptomic, chromatin accessibility, and genomic profiles. The MBC-like subtype is unable to differentiate beyond the MBC stage, upregulates key MBC genes, and is characterized by upregulated B-cell receptor and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling. In contrast, the PC-like subtype can partially differentiate toward a PC, upregulates key PC genes, has enhanced NF-κB signaling, and has an upregulated unfolded protein response. Pseudotime trajectory analysis of combined single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin with sequencing supports the variable differentiation capacity of each subtype and implicate key transcription factors SPI1, SPIB, BCL11A, and XBP1 in these features. The existence and generalizability of the 2 disease subtypes were validated further using hierarchical clustering of bulk RNA-sequencing data from a secondary set of patients. The biological significance of the subtypes was further established using whole-genome sequencing, in which it was shown that CXCR4, NIK, and ARID1A mutations occur predominantly in the MBC-like subtype, and 6q deletions in the PC-like subtype. We conclude that the variable differentiation blockade seen in WM manifests itself clinically as 2 disease subtypes with distinct epigenetic, mutational, transcriptional, and clinical features, with potential implications for WM treatment strategies.

14 December 2021 in Biomaterials Science
Verified
Journal Article
Open access
PDF file
TVThibault Voeltzel
Thibault Voeltzel
GFGaëlle Fossard
Gaëlle Fossard
MDMichaël Degaud
Michaël Degaud
KGKevin Geistlich
Kevin Geistlich
NGNicolas Gadot
Nicolas Gadot
VMVeronique Maguer-satta
Veronique Maguer-satta
We provide an easy to access microphysiological standardized system approaching the human bone marrow complexity to a first level of analysis by in situ imaging or by viable cell harvesting of processes taking place within this ecosystem.

13 March 2023 in Leukemia
Verified
Journal Article
Closed access
PDF file
MAMarine Armand
Marine Armand
MDMichaël Degaud
Michaël Degaud
BTBruno Tesson
Bruno Tesson
CLCécile Laurent
Cécile Laurent
MVManon Vavasseur
Manon Vavasseur
LCLucile Couronné
Lucile Couronné

4 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
MDMichaël Degaud
Michaël Degaud
LBLucile Baseggio
Lucile Baseggio
BGBéatrice Grange
Béatrice Grange
DMDelphine Manzoni
Delphine Manzoni
SHSarah Huet
Sarah Huet
PSPierre Sujobert
Pierre Sujobert
According to the World Health Organization (WHO) classification, the nosology of B-cell neoplasms integrates clinical, morphological, phenotypic, and genetic data. In this retrospective analysis, we identified 18 patients with isolated neoplastic lymphocytosis that could not be accurately classified within the WHO classification. Most of them were asymptomatic at the time of diagnosis and the evolution was relatively indolent, as only five patients required treatment after a median follow-up of 48 months. The neoplastic B-cells expressed CD5 in most cases, but the Royal Marsden Hospital score was strictly below 3. Trisomy 12 was the most frequent cytogenetic abnormality. High-throughput sequencing highlighted mutations found in both chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). Similarly, the immunoglobulin heavy chain variable region repertoire was distinct from those reported in CLL or MZL. However, as treatment choice is dependent on the correct classification of the lymphoproliferative disorder, a histological diagnosis should be performed in case patients need to be treated.